Bhopal/Jabalpur: Issuing notices to the National Medical Commission (NMC) and the Madhya Pradesh Medical Science University, ...

Nearly 600 attendees learned about life sciences industry trends and heard from 93 presenting biotechnology companies at ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

The COVID-19 pandemic underscored the urgency for swift, scalable drug production, sparking a surge in investment toward new production facilities. The demand for these facilities shows no signs ...

Numbers have since fallen, probably at least in part because of coronavirus-related lockdowns, coming in 13 cases in 2020 and 49 in 2021, according to Centers for Disease Control and Prevention ...

Is foreign capital associated with economic growth and, if not, why does it flow "uphill"? Standard economic theory tells us that financial capital should, on net, flow from richer to poorer countries ...

Effective KOL management is more than just tracking which activities your KOLs have engaged with. It’s also about tracking the effectiveness of those activities, and the resulting impact on KOL ...

To fight summer load shedding, the Guam Power Authority wants to cut a deal to have the Ukudu power plant feeding energy into the grid a few months ahead of schedule. GPA General Manager John ...

Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi. In the latest development, the European Commission has ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...